RVLP News and Press, RVL Pharmaceuticals plc From 12/01/22

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a panel presentation and host 1x1...

RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer JD Schaub – Chief Operating Officer Mike DePetris ...

RVL Pharmaceuticals plc press release ( NASDAQ: RVLP ): Q3 GAAP EPS of -$0.16 in-line. Revenue of $10.02M (+357.5% Y/Y) in-line. For further details see: RVL Pharmaceuticals plc GAAP EPS of -$0.16 in-line, revenue of $10.02M in-line

-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 202...

BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%,...

New Jersey-based RVL Pharmaceuticals ( NASDAQ: RVLP ) announced on Tuesday that the company generated nearly $10M net product sales for its eye disease therapy Upneeq in 3Q 2022, implying a sequential growth of ~19%. Upneeq is indicated for adults with acquired b...

--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales growth contributed to approximately $24.4 million in sales for the nine months ended ...

Summary RVL Pharmaceuticals shares have performed admirably over the last quarter. UPNEEQ appears well short of its ambitious revenue guidance for Q4, 2022. Q3 promises to present further challenges to the UPNEEQ growth narrative. Liquidity will be an existential challenge...

The following slide deck was published by RVL Pharmaceuticals plc in conjunction with this event. For further details see: RVL Pharmaceuticals (RVLP) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow

BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 24 th ...